Copenhagen, Denmark, January 19, 2016 – – Vipergen ApS, a biotechnology company focused on small molecule drug discovery using its proprietary second
generation DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Gilead Sciences, Inc.
Under the terms of the agreement, Vipergen is applying its small molecule discovery engine, which leverages a high fidelity proprietary DNA-encoded library platform, to identify novel hits/leads for protein targets specified by Gilead. Gilead obtains exclusive options to selected hits and hit series discovered in the course of the collaboration. Other terms of the agreement were not disclosed.
“We are thrilled to work with Gilead, one of the world’s leading biopharmaceutical companies, on targets which are difficult from a drug discovery standpoint,” said Nils Hansen, Ph.D., Chief Executive Officer of Vipergen. “Vipergen has designed and implemented its discovery engine to meet the challenges of such highly difficult targets.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
About Vipergen ApS
Vipergen is dedicated to small molecule drug discovery using DNA-encoded library platforms.
Vipergen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.
Vipergen´s two second generation technology platforms – The YoctoReactor® for synthesizing DNAencoded chemical libraries and Binder Trap Enrichment® for screening of such libraries – are designed to deliver high fidelity drug discovery.
For further details about Vipergen and the YoctoReactor® / Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact:
Vipergen ApS
Dr. Nils Hansen, Chief Executive Officer
Phone: +45 2523 6680
[email protected]